← Back to Search

Unknown

LY3561774 for Mixed Dyslipidemia (PROLONG-ANG3 Trial)

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must be on a stable moderate or high-intensity dose of a statin for at least 2 months before screening and remain on the same medication and dose for the duration of the study
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 270
Awards & highlights

PROLONG-ANG3 Trial Summary

This trial is testing a new drug to see if it's effective and safe for people with mixed dyslipidemia who are already taking a statin.

Who is the study for?
This trial is for adults with mixed dyslipidemia who have high LDL cholesterol (≥100 mg/dL) and triglycerides (200-499 mg/dL), a BMI of 18.5 to 40 kg/m², and are on a stable statin dose. Excluded are those with recent severe cardiovascular events, heart failure, procedures affecting lipids or obesity surgery within the last year, uncontrolled hypertension or diabetes.Check my eligibility
What is being tested?
The study tests LY3561774's effectiveness in lowering lipid levels compared to placebo in participants with mixed dyslipidemia already taking statins. It's a Phase 2b trial where patients receive either the drug or placebo through injections while their usual statin treatment continues.See study design
What are the potential side effects?
Potential side effects of LY3561774 may include reactions at the injection site, changes in liver enzymes or fat levels that could affect organ function, muscle pain or weakness especially when combined with statins.

PROLONG-ANG3 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been on a consistent dose of a strong statin for at least 2 months.

PROLONG-ANG3 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 270
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to day 270 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent Change from Baseline for Apolipoprotein B (ApoB)
Secondary outcome measures
Percent Change from Baseline for ANGPTL3
Percent Change from Baseline for Angiopoietin-like (ANGPTL3)
Percent Change from Baseline for ApoB
+8 more

PROLONG-ANG3 Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3561774 Dose 3Experimental Treatment1 Intervention
Participants will receive LY3561774 SC
Group II: LY3561774 Dose 2Experimental Treatment1 Intervention
Participants will receive LY3561774 SC
Group III: LY3561774 Dose 1Experimental Treatment1 Intervention
Participants will receive LY3561774 subcutaneously (SC)
Group IV: PlaceboPlacebo Group1 Intervention
Participants will receive placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3561774
2020
Completed Phase 1
~80

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,615 Previous Clinical Trials
3,200,883 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,344 Previous Clinical Trials
405,077 Total Patients Enrolled

Media Library

LY3561774 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT05256654 — Phase 2
Lipid Disorders Research Study Groups: LY3561774 Dose 1, LY3561774 Dose 2, LY3561774 Dose 3, Placebo
Lipid Disorders Clinical Trial 2023: LY3561774 Highlights & Side Effects. Trial Name: NCT05256654 — Phase 2
LY3561774 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05256654 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many venues are actively overseeing this clinical trial?

"This research study is taking place in 12 locations, including Waterbury, Oxon Hill and Fall River. If you are interested to take part in the trial, it may be prudent to select a location closest to your residence for convenience."

Answered by AI

How many individuals have registered for this research project?

"This trial requires 175 eligible individuals to contribute. Enrollees can be sourced from Chase Medical Research, LLC in Waterbury, Connecticut and MD Medical Research in Oxon Hill, Maryland - amongst other locations."

Answered by AI

Is enrolment for this trial still open to prospective participants?

"The information on clinicaltrials.gov reveals that this research project is still open for recruitment. It was first available to the public on July 20th, 2022 and its most recent update occurred November 24th of the same year."

Answered by AI

Is LY3561774 a viable option from an efficacy and safety perspective?

"Drawing on a scale of 1 to 3, our experts at Power rated the safety profile of LY3561774 as 2 due to available evidence suggesting its safe use but no data yet supporting any efficacy."

Answered by AI

Who else is applying?

What state do they live in?
Pennsylvania
How old are they?
18 - 65
What site did they apply to?
Preferred Primary Care Physicians
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study of LY3561774 in Participants With Mixed Dyslipidemia
2022. "A Study of LY3561774 in Participants With Mixed Dyslipidemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05256654.
~66 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top